Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
7 hedge funds and large institutions have $704 invested in Sorrento Therapeutics, Inc. in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
22% less funds holding
Funds holding: 9 → 7 (-2)
95% less capital invested
Capital invested by funds: $13.9K → $704 (-$13.2K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCOV
Trust Company of Vermont
Brattleboro,
Vermont
|
-$25 |
SRNE Hedge Fund Activity: Q1 2024 in Review
7 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2024, worth a combined $704 — down 95% from $13.9K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SRNE and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Trust Company of Vermont, exiting entirely with an estimated $25 sold.
- 7 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2024, down from 9 in Q4 2023.
- Funds reported $704 of Sorrento Therapeutics, Inc. stock for Q1 2024, down 95% quarter-over-quarter.
- 0 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2024 and 2 closed out, a net change of -2 holders.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2024 was Trust Company of Vermont, an estimated $25 sold.
Based on aggregated 13F filings for Q1 2024.